Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
Go back to Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference| (NASDAQ: TBPH) | Delayed: 17.03 -0.01 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.04 | 52 Week High | $38.92 | |||
| Open | $17.03 | 52 Week Low | $12.87 | |||
| Day High | $17.04 | P/E | N/A | |||
| Day Low | $17.03 | EPS | $0.00 | |||
| Volume | 64,997 | |||||
